Current Gene Therapy is a bi-monthly peer-reviewed journal aimed at academic and industrial scientists with an interest in major topics concerning basic research and clinical applications of gene and cell therapy of diseases. Cell therapy manuscripts can also include application in diseases when cells have been genetically modified. Current Gene Therapy publishes full-length/mini reviews and original research on the latest developments in gene transfer and gene expression analysis, vector development, cellular genetic engineering, animal models and human clinical applications of gene and cell therapy for the treatment of diseases.
Current Gene Therapy publishes reviews and original research containing experimental data on gene and cell therapy. The journal also includes manuscripts on technological advances, ethical and regulatory considerations of gene and cell therapy. Reviews should provide the reader with a comprehensive assessment of any area of experimental biology applied to molecular medicine that is not only of significance within a particular field of gene therapy and cell therapy but also of interest to investigators in other fields. Authors are encouraged to provide their own assessment and vision for future advances. Reviews are also welcome on late breaking discoveries on which substantial literature has not yet been amassed. Such reviews provide a forum for sharply focused topics of recent experimental investigations in gene therapy primarily to make these results accessible to both clinical and basic researchers. Manuscripts containing experimental data should be original data, not previously published.
Liang Cheng College of Bioinformatics Science and Technology Harbin Medical University Harbin, Heilongjiang (China)
Dr. Cheng obtained a doctorate (Ph.D.) in Bioinformatics from Harbin
Institute of Technology, Harbin, Heilongjiang, China. Currently Dr. Cheng
is a Professor and PI of Biological Software Engineering in Harbin Medical
University. He has published more than 70 scientific publications since
2013. Dr. Cheng develops novel algorithms and tools for gene therapy of
Type 2 Diabetes Mellitus and complex diseases.